or Try an Advanced Search...

    Nephritis Stocks List

    Symbol Grade Name % Change
    AUPH F Aurinia Pharmaceuticals Inc 2.16
    BIIB C Biogen Idec Inc. 0.61
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Immunosuppressants Lupus Lupus Nephritis Medicine Alzheimer's Disease Autoimmune Disease Autoimmune Disorders Biopharmaceutical Biotechnology Cd20 Chronic Lymphocytic Leukemia Clinical Development Clinical Trial Product Clinical Trial Products Degenerative Disease Disability Drugs Hemophilia Idiopathic Pulmonary Fibrosis Immune Disorders

    Related ETFs - A few ETFs which own one or more of the above listed Nephritis stocks.

    Symbol Grade Name Weight
    BIS B ProShares UltraShort Nasdaq Biotechnology 6.12
    PBE C PowerShares Dynamic Biotech & Genome 4.61
    DIP A BTD Capital Fund 4.41
    BBH D Market Vectors Biotech ETF 4.17
    IBRN C iShares Neuroscience and Healthcare ETF 4.16
    View all Nephritis ETFs...
    Compare ETFs
    Compare BBH to IBRN Compare DIP to BBH Compare PBE to DIP

        Nephritis Stocks Recent News

        Date Stock Title
        May 1 AUPH Aurinia Pharma Q1 2024 Earnings Preview
        May 1 AUPH Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
        Apr 30 BIIB Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings
        Apr 30 AUPH Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going
        Apr 30 BIIB Biogen: Don't Overthink This One
        Apr 30 AUPH Aurinia gains on Lupkynis label update
        Apr 30 AUPH The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
        Apr 29 BIIB The Analyst Landscape: 27 Takes On Biogen
        Apr 29 BIIB 10 Most Promising Stocks to Buy Before They Take Off
        Apr 29 BIIB Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)
        Apr 29 BIIB Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
        Apr 28 BIIB Biogen First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        Apr 27 BIIB Biogen Inc. (NASDAQ:BIIB) Just Released Its First-Quarter Earnings: Here's What Analysts Think
        Apr 26 BIIB Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
        Apr 26 BIIB The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
        Apr 26 BIIB Decoding Biogen Inc (BIIB): A Strategic SWOT Insight
        Apr 25 BIIB Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
        Apr 25 BIIB Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
        Apr 25 BIIB Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript
        Apr 25 BIIB Shareholders 30% loss in Biogen (NASDAQ:BIIB) partly attributable to the company's decline in earnings over past year
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Immunosuppressants Lupus Lupus Nephritis Medicine Alzheimer's Disease Autoimmune Disease Autoimmune Disorders Biopharmaceutical Biotechnology Cd20 Chronic Lymphocytic Leukemia Clinical Development Clinical Trial Product Clinical Trial Products Degenerative Disease Disability Drugs Hemophilia Idiopathic Pulmonary Fibrosis Immune Disorders
        Nephritis

        Nephritis is inflammation of the kidneys and may involve the glomeruli, tubules, or interstitial tissue surrounding the glomeruli and tubules.

        More about Nephritis
        Browse All Tags